GSK to donate 50 million doses of H1N1 vaccine for developing countries

LONDON — GlaxoSmithKline on Nov. 10 announced that it has signed an agreement with the World Health Organization to donate 50 million doses of its adjuvanted pandemic H1N1 influenza vaccine for distribution to developing countries most in need.

GSK is working with WHO and health authorities to prepare for initial shipments of the vaccine to developing countries by the end of November.

“GSK is committed to supporting governments and health authorities around the world in their efforts to protect their populations against this pandemic,” said Andrew Witty, CEO of GlaxoSmithKline.

In addition to the donation made to WHO, GSK is also supplying its vaccine to developing countries under a tiered pricing policy, based on World Bank Classification and GAVI eligibility. GAVI–eligible countries, which include the world’s poorest, would receive highly preferential prices, based on volume orders. GSK has allocated 20 percent of overall production of its Canadian manufacturing site to developing countries. The donation to WHO is part of this allocation.

"WHO will now work to see that these vaccines are distributed to those who need them," said Dr. Margaret Chan, director–general of the WHO.